Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

Article Abstract:

A 24-week randomized, open-label, noninferiority trial was conducted comparing oral mycophenolate mofetil with monthly intravenous cyclophosphamide as induction therapy for active lupus nephritis. In the 24-week trial, mycophenolate mofetil was more effective than intravenous cyclosphophamide in inducing remission of lupus nephritis and had a more favorable safety profile.

Author: Appel, Gerald B., Wallace, Daniel J., Petri, Michelle, Weisman, Michael H., Ginzier, Ellen M., Dooley, Mary Anne, Aranow, Cynthia, Kim, Mimi Y., Buyon, Jill, Gilkeson, Gary S., Merrill, Joan T.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United States, Care and treatment, Clinical trials, Comparative analysis, Dosage and administration, Cyclophosphamide, Mycophenolate mofetil, Nephritis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis

Article Abstract:

The drug mycophenolate mofetil can be used instead of cyclophosphamide when treating patients with lupus kidney disease. In a study of 42 patients, half took one drug and half the other, both in combination with prednisolone. Most of the serious side effects occurred in patients taking cyclophosphamide.

Author: Chan, Tak Mao, Li, Fu Keung, Tang, Colin S.O., Wong, Raymond W.S., Tong, Matthew K.L., Chan, Kwok Wah, Lai, Kar Neng
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Treatment of lupus nephritis -- a work in progress

Article Abstract:

The drug mycophenolate mofetil may be effective in treating lupus kidney disease with fewer side effects than other treatments. Most patients are given immunosuppressive drugs, which can have severe side effects.

Author: Falk, Ronald J.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Editorial

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Systemic lupus erythematosus, Kidney diseases
Similar abstracts:
  • Abstracts: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial
  • Abstracts: Bilateral transvaginal sacrospinous colpopexy: preliminary experience. Vaginal subtotal hysterectomy and sacrospinous colpopexy: an option in the management of uterine prolapse
  • Abstracts: Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. Regional Brain Volume Abnormalities and Long-term Cognitive Outcome in Preterm Infants
  • Abstracts: Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss
  • Abstracts: Laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy: a prospective, randomized, multicenter study
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.